Events News Research CBS CBS Publications Bioinformatics
Staff Contact About Internal CBS CBS Other

2014 (4) 2013 (5) 2012 (2) 2011 (7) 2010 (4)


    STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes
    Xiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, Kroll Y, Boldin M, Taganov K, Groner B, Richardson AL, Frank DA
    Science Signaling. 2014 Jan 28;7(310):ra11, 2014
    Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study.
    Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C
    PLoS Biology. 2014 Jul 8;12(7):e1001906, 2014
    Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
    Hatzis C, Bedard PL, Birkbak NJ, Beck AH, Aerts HJ, Stern DF, Shi L, Clarke R, Quackenbush J, Haibe-Kains B
    Cancer Research. 2014 Aug 1;74(15):4016-4023, 2014
    Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers.
    Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, Pickering L, Gore M, Larkin J, Szallasi Z, Bates PA, Swanton C, Gerlinger M
    European Urology. 2014 Jul 18. pii: S0302-2838(14)00627-7., 2014


    Computational optimisation of targeted DNA sequencing for cancer detection
    Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C
    Scientific Reports 3:3309 doi:10.1038/srep03309, 2013
    Inconsistency in large pharmacogenomic studies
    Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJWL, Quackenbush J
    Nature (2013/11/27 ) doi:10.1038/nature12831, 2013
    HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis.
    Adelman CA, Lolo RL, Birkbak NJ, Murina O, Matsuzaki K, Horejsi Z, Parmar K, Borel V, Skehel JM, Stamp G, D\\\'Andrea A, Sartori AA, Swanton C, Boulton SJ
    Nature 502(7471):381-4 doi:10.1038/nature12565, 2013
    Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
    Birkbak NJ, Kochupurakkal B, Izarzugaza JMG, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC
    Research Article | published 12 Nov 2013 | PLOS ONE 10.1371/journal.pone.0080023, 2013
    Parallel evolution of tumor subclones mimics diversity between tumors.
    Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell R, Rowan A, Joshi T, Fisher R, Larkin J, Szallasi Z, Swanton C
    The Journal of Pathology. 230(4):356-64 doi:10.1002/path.4214, 2013
    Relevant URL


    Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents
    Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL
    Cancer Discovery 2(4):366-75 doi:10.1158/2159-8290.CD-11-0206, 2012
    Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
    Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, Defazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD; for the Australian Ovarian Cancer Study Group, Matulonis UA
    Clin. Cancer Res. 18(20):5806-15 doi:10.1158/1078-0432.CCR-12-0857, 2012


    Chromosomal instability confers intrinsic multidrug resistance
    Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C
    Cancer Res. 71(5):1858-70 doi:10.1158/0008-5472.CAN-10-3604, 2011
    A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables
    Endesfelder D, McGranahan N, Birkbak NJ, Szallasi Z, Kschischo M, Graham TA, Swanton C
    Oncotarget 2(7):529-37, 2011
    CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction
    Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, Jones NP, East P, Nicke B, Spassieva S, Obeid LM, Birkbak NJ, Szallasi Z, McKnight NC, Rowan AJ, Speirs V, Hanby AM, Downward J, Tooze SA, Swanton C
    The Journal of Pathology. 226(3):482-94 doi:10.1002/path.2998, 2011
    Jetset: selecting the optimal microarray probe set to represent a gene
    Li Q, Birkbak NJ, Gyorffy B, Szallasi Z, Eklund AC
    BMC Bioinformatics 12:474 doi:10.1186/1471-2105-12-474, 2011
    Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer
    Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Szallasi Z, Kschischo M, Swanton C
    Cancer Epidemiol. Biomarkers Prev. 20(10):2183-94 doi:10.1158/1055-9965.EPI-11-0343, 2011
    Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
    Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kains B, Sotiriou C, Symmans WF, Pusztai L, Brunak S, Richardson AL, Szallasi Z
    BMC Bioinformatics 12:310 doi:10.1186/1471-2105-12-310, 2011
    Paradoxical relationship between chromosomal instability and survival outcome in cancer
    Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C
    Cancer Res. 71(10):3447-52 doi:10.1158/0008-5472.CAN-10-3667, 2011


    Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER Status
    Li Q, Eklund AC, Juul N, Haibe-Kains B, Workman CT, Richardson AL, Szallasi Z, Swanton C
    PLoS ONE 5(12):e15031 doi:10.1371/journal.pone.0015031, 2010
    Targeting chromosomal instability and tumour heterogeneity in HER2 positive breast cancer
    Burrell RA, Juul N, Johnston SR, Reis-Filho J, Szallasi Z, Swanton C
    J. Cell. Biochem. 111(4):782-90 doi:10.1002/jcb.22781, 2010
    Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
    Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C
    Lancet Oncol. 11(4):358-65 doi:10.1016/S1470-2045(10)70018-8, 2010
    Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
    Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE
    Journal of Clinical Oncology. 28(7):1145-53 doi:10.1200/JCO.2009.22.4725, 2010

2014 (4) 2013 (5) 2012 (2) 2011 (7) 2010 (4)